References
- Ruggeri ZM, Zimmerman RS. Von Willebrand factor and von Willebrand disease. Blood 1987;70:895–904.
- James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, et al.. The mutual spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007;109:145–54.
- Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc 2002;77:181–7.
- Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, et al.. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998;91:3623–9.
- Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520–5.
- Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al.. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–74.
- Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006;32:456–71.
- Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006;81:616–23.
- Mohri H, Hisanaga S, Mishima A, Fujimoto S, Uezono S, Okubo T. Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma: recognition sites present on the A1 loop and A3 domains of von Willebrand factor. Blood Coagul Fibrinolysis 1998;9:91–7.
- van Genderen PJ, Vink T, Mishiels JJ, van ‘t Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994;84:3378–84.
- Scrobohaci ML, Daniel MT, Levy Y, Marolleau JP, Brouet JC. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993;84:471–5.
- Richard C, Cuadrado MA, Prieto M, Batlle J, López Fernández MF, Rodriguez Salazar ML, et al.. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol 1990;35:114–7.
- Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand’s disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol 1997;96:850–3.
- Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997;23:425–31.
- Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, et al.. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000;102:1290–5.
- Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9.
- Eby CS. Bleeding and thrombosis risks in plasma cell dyscrasias. Hematol Am Soc Hematol Educ Program 2007:158–64.
- Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al.. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Haematol J 2003;4:379–98.
- Salzman EW. Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in von Willebran’s disease. J Lab Clin Med 1963;62:724–35.
- Born GV, Gross MJ. The aggregation of blood platelets. J Physiol 1963;168:178–95.
- Sagan Z. The application of Rivanol for serum transferin and immunoglobulin G determination. Clin Chem Acta 1968;21:225–31.
- Johansen BG. Agarose gel electrophoresis. Scand J Clin Lab Invest 1972;124:7–9.
- Mejbaum-Katzenellenbogen W. Turbidimetric micromethod of determination of proteins with tannin. Acta Biochim Pol 1955;2:279–94.
- Shinagawa A, Kojima H, Bernt MC, Kaneko S, Suzukawa K, Hasegawa Y, et al.. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost 2005;93:889–96.
- Mohri H, Tanabe J, Ohtsuka M, Yoshida M, Motomura S, Nishida S, et al.. Acquired von Willebrand disease associated with multiple myeloma: characterization of an inhibitor to von Willebrand factor. Blood Coagul Fibrinolysis 1995;6:561–6.
- Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophisiology to management. Thromb Haemost 2000;84:175–82.
- Fricke WA, Brinkhous KM, Garris JB, Roberts HR. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood 1985;66:562–9.